48TiP TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer

Journal article

Peer reviewed

B.M. Slomovitz, B.J. Monk, K.S. Tewari, N. Cloven, A. Farolfi, A. Ferrero, D. Cibula, C. Dubot, L. Barraclough, L. Fariñas Madrid, …

ESMO open, Vol.11, p.108073

07/2026

Files and links (1)

url

https://doi.org/10.1016/j.esmoop.2026.108073View

Published (Version of record) Open

1 Record Views

Title: 48TiP TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer
Creators: B.M. Slomovitz - Mount Sinai Medical Center
B.J. Monk - Florida Cancer Specialists & Research Institute
K.S. Tewari - University of California, Irvine
N. Cloven - Texas Oncology
A. Farolfi - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
A. Ferrero - A. O. Ordine Mauriziano di Torino
D. Cibula - Charles University
C. Dubot - Centre François Baclesse
L. Barraclough - The Christie NHS Foundation Trust
L. Fariñas Madrid - Vall d'Hebron Hospital Universitari
et al.
Publication Details: ESMO open, Vol.11, p.108073
Publisher: Elsevier Ltd
Identifiers: 991006292257202656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article